A recent study published in the New England Journal of Medicine highlights that a significant number of young adults, particularly those aged 18 to 29, are showing signs of arterial plaque. This finding challenges the common belief that heart disease primarily affects older indi…
SCOPE School Malaysia 2026 is a one-day educational program focused on evidence-based obesity management, organized by Universiti Malaya in collaboration with local obesity societ…
A recent international study indicates that atherosclerosis, a condition characterized by plaque buildup in the arteries, is more prevalent among young adults than previously reco…
Eli Lilly's experimental obesity treatment, combining eloralintide and Mounjaro, has demonstrated an average weight loss of 23% in individuals with diabetes, highlighting its pote…
Recent developments in weight-loss medications highlight the potential of amylin-based drugs, which may offer effective weight management with fewer gastrointestinal side effects…
Recent lawsuits have emerged against the makers of GLP-1 drugs like Ozempic and Wegovy, alleging insufficient warnings about a rare vision loss condition known as NAION. While stu…
Numerous lawsuits have been initiated in the United States against companies producing GLP-1 medications, such as Ozempic and Mounjaro, claiming these drugs may lead to a rare eye…
A recent study from Karolinska Institutet reveals that gut microbes can convert nitrate and non-heme iron from vegetables into dinitrosyl iron complexes (DNICs), which may offer h…
The FDA has approved Eli Lilly's medication Mounjaro for reducing the risk of heart events in individuals with Type 2 diabetes. This approval adds to the drug's existing use for b…
Experts advise that individuals taking oral GLP-1 medications like Wegovy should avoid consuming coffee or tea at the same time to ensure proper absorption of the medication. The…
The death of 19-year-old Josephine Nasr, a law student in London, has sparked serious concerns regarding the safety of tirzepatide, a GLP-1 weight loss drug. Following her prescri…
Nestle is leveraging the rise of GLP-1 weight-loss drugs to create new products aimed at consumers taking medications like Ozempic and Wegovy. The company is utilizing artificial…
Novo Nordisk's stock fell by 7% after the company revealed its long-term growth strategy at a capital markets day, raising investor concerns about its ability to maintain its posi…
Eli Lilly is targeting a revenue milestone of $100 billion by fiscal 2026, supported by strong growth in its incretin franchise and a bullish price target of $1,480. The company's…